BioSpace News Archive

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a “Study May Proceed” letter from the US Food and Drug Administration (FDA) to begin a Phase Ib study evaluating CX-5461,

The global hypothyroidism drug market is expected to witness significant growth in the forecast period, 2020 to 2030 on account of increasing cases of thyroid worldwide.

Patient monitoring accessories are supplemental gadgets that are used with patient monitoring clinical devices to deliver efficient and timely treatment

After a capital increase in the initial closing of its series A round, with investments by Mitsubishi UFJ Capital and Real Tech Fund, Epsilon Molecular Engineering Inc., a Saitama University-based biotechnology startup, recently had its second closing.

Alentis Therapeutics announced that Prof. Thomas Baumert, its founder and world-leading authority in the field, has been awarded the Mémain-Pelletier, French Academy of Science award for his ground-breaking research into understanding the pathogenesis of liver cancer.

Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.

The J.P. Morgan Healthcare Conference, the largest investment conference in the life science industry, will take place January 11-14, 2021

MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease.

Strategic acquisition further establishes symplr as the healthcare governance, risk management, and compliance software leader

Rakuten Medical, Inc. announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas.